Living with COPD? Learn More

COPD Clinical Study | Sanofi
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
What are the PERSEPHONE and THESEUS clinical studies?
Who can Participate?
FAQ
See if you pre-qualify
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
SanofiStudies.com
Am I Eligible?
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
Is COPD disrupting your daily life?
If you or a loved one have Chronic Obstructive Pulmonary Disease (COPD), you may be interested in learning more about the PERSEPHONE and THESEUS clinical studies.
See if you may pre-qualify
Short Summary
Medical Condition:
Chronic Obstructive Pulmonary Disease (COPD)
Participation duration:
Approximately 14 months
Phase:
2b/3
Are one of these clinical studies a match for you?
What is Chronic Obstructive Pulmonary Disease (COPD)?
Chronic Obstructive Pulmonary Disease, commonly known as COPD, is a lung disease that is usually diagnosed using special breathing tests that measure how well your lungs are working. People with COPD often experience shortness of breath, frequent coughing, tiredness, wheezing, and produce excess mucus. Everyday activities such as walking, cooking, or doing housework can become tiring. COPD usually starts after years of damage to the lungs, often from smoking or breathing in air pollution.
There are two main parts of the disease:
Flare-ups - times when symptoms suddenly worsen, often triggered by infections and sometimes requiring hospitalisation.
Slow loss of lung strength over time and breathing gradually becoming more difficult.
Managing COPD involves treating symptoms, preventing flare-ups, and slowing the progression of the disease.
Find out if a COPD clinical study might be a match for you.
Please answer a few questions to see if you may qualify for a clinical study.
With your consent, we (Trialbee) will collect and use the information you submit here to indicate your interest in participating in a clinical study, and to see if you are eligible to move to the next stage of screening.
During the next stage, you will be contacted by Trialbee to ask some additional questions to further assess your eligibility and discuss clinical study participation.
Get started
See if you Pre-Qualify
Enter contact information
Submitted
Please answer the following questions to find out if you are suitable for a COPD clinical study.
How old are you?
Under 40
40 to 80 years old
More than 80 years old
Next
Preview complete
The prescreener preview is complete. You may now close the preview.
What are the PERSEPHONE and THESEUS clinical studies?
PERSEPHONE and THESEUS are two clinical studies that are testing the same investigational study medicinal product. The investigational study medicinal product is a type of medicine that works by targeting specific pathways of inflammation related to some COPD symptoms. The main objectives of these two studies is to learn how the investigational study medicinal product impacts:
COPD flare-ups (or exacerbations)
Lung function
Quality of life
These clinical studies are investigating how well the investigational study medicinal product works for patients with moderate to severe COPD and who are either current smokers or have a history of smoking.
The PERSEPHONE and THESEUS clinical studies are randomised, double-blind, placebo-controlled clinical studies. In these studies, two medicinal product dose regimens are tested. This has no impact on your study visit schedule, but it means that you have a 2 out of 3 chance of receiving the investigational study medicinal product, and a 1 out of 3 chance of receiving placebo.
Randomisation means that a computer will randomly assign participants to receive either the investigational study medicinal product or placebo.
Double-blind means that neither you nor your study doctor will know whether you are receiving the investigational study medicinal product or placebo.
The placebo looks like the investigational study medicinal product but does not contain any active medication.
The investigational study medicinal product is not approved by health authorities such as the Medicines and Healthcare products Regulatory Agency (MHRA) and is still under investigation for the treatment of COPD, so its effectiveness and safety have not been established.
Who can participate?
You may be eligible* to participate if you:
Are between the ages of 40 – 80 years old
Have had a diagnosis of COPD for at least 1 year
Are a current or former smoker
Have had at least 2 COPD flare-ups in the last year, or have been hospitalised in the last year for a COPD flare-up
Are taking daily treatments for your COPD
*Please note there are more eligibility criteria that must be met to be considered for participation.
See if you Pre-Qualify
What happens if I participate?
The clinical studies are divided into periods:
Screening Period
(typically between 2 and 4 weeks – [1 study site visit])
The study doctor and team at the study site will assess your eligibility for one of the clinical studies, and the decision to participate will be yours to make. Once specific tests and assessments are completed, and you meet all the required criteria for participation, the treatment period of the clinical study will begin. Throughout your participation, you will also be asked to use an electronic diary (e-diary) once a day to answer a few simple questions about your health and to record the COPD medicines you actually took. Your e-diary will be reviewed with the study team during your study site visits.
Study Treatment Period
(48 weeks – [14 study site visits])
During this period, you will receive either the investigational study medicinal product, or a placebo. A placebo will look like the investigational study medicinal product but does not contain any active medications. Both the investigational study medicinal product and placebo will be administered as a subcutaneous (under the skin) injection. The study team will provide you with information regarding the likelihood of which one you will receive. Neither you nor the study team will know whether you are taking the investigational study medicinal product or placebo during the study treatment period. The study treatment period will last 48 weeks and will require 14 visits to the study site. During your visits to the study site, you will receive your injection and undergo additional tests, including blood draws, smoking status checks, and breathing tests conducted by the study team. The study doctor and team will monitor your progress closely.
Follow up Period
(8 weeks – [1 study site visit])
Eight weeks after the Study Treatment Period ends, you will go back to see the study doctor for a safety check-up.
Your study doctor will be able to provide more detailed information on what will happen if you decide to participate.
How do I take part?
Complete the online questions to see if you pre-qualify.
Submit your contact information.
Answer our phone call to answer more questions to help us determine if you are eligible.
Confirm your interest and preferred study site location.
Speak with the study site about the next steps to participate.
CHECK IF YOU PRE-QUALIFY
Frequently Asked Questions:
What will happen after I complete the online questionnaire?
Should your online questionnaire suggest that you are potentially eligible, a qualified medical professional will contact you to conduct a more comprehensive telephone medical assessment and further evaluate your eligibility. Upon confirmation of your potential eligibility during the telephone medical assessment, you will be presented with nearby study sites conducting one of the clinical studies. The study site of your choice will be provided with your contact d…

Text scraped from the landing page for research purposes. © respective owners. This text is sourced from the advertiser's public landing page; for removal, contact dmca@luba.media.